Therapeutic innovations in endocrine diseases - Part 4 : Pasireotide: Long-acting release somatostatin analogue.
Pasireotide, the latest long-acting release somatostatin analogue, is distributed more widely to the various somatostatin receptors, which theoretically increases its strength and broadens its scope. Does this reflect genuine therapeutic progress? Or rather does its reduced specificity cause too many adverse reactions to make it a significant therapeutic achievement?